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Background: Growth is an essential outcome measure for evaluating the safety of any new ingredients, including
probiotics, added to infant formulae. The aim of this systematic review was to determine the effects of supplementation
of infant formulae with Bifidobacterium lactis Bb12 (B lactis) and/or Lactobacillus rhamnosus GG (LGG) compared with
unsupplemented formula on the growth of healthy infants.
Methods: The MEDLINE, EMBASE, and Cochrane Library databases were searched in June 2013 for relevant randomized
controlled trials (RCTs) conducted in healthy term infants. Unpublished data were obtained from the manufacturer of
B lactis-supplemented formula. The primary outcome measures were weight, length, and head circumference.
Results: Nine eligible trials were identified. Compared with unsupplemented controls, supplementation of infant formula
with B lactis had no effect on weight gain [4 RCTs, n = 266, mean difference (MD) 0.96 g/day, 95% confidence interval
(CI) -0.70 to 2.63)], length gain (4 RCTs, n = 261, MD −0.39 mm/month, 95% CI −1.32 to 0.53), or head circumference gain
(3 RCTs, n = 207, MD 0.56 mm/month, 95% CI −0.17 to 1.30). Data limited to one small (n = 105) trial suggest that infants
who received standard infant formula supplemented with LGG grew significantly better. No such effect was observed in
infants fed hydrolyzed formula supplemented with LGG.
Conclusions: Supplementation of infant formula with B lactis results in growth similar to what is found in infants fed
unsupplemented formula. Limited data do not allow one to reach a conclusion regarding the effect of LGG
supplementation on infant growth.
Keywords: Feeding, Growth, Probiotics, Infants, ChildrenBackground
Growth is a sensitive, although nonspecific, sign of the
overall health and nutritional status of an infant. It is
also an essential outcome measure for evaluating the
safety of any new ingredient added to infant formulae
such as probiotics. Generally, growth studies should
include at least measurements of weight and length
velocity and head circumference [1].
In 2010, the Committee of Nutrition of the European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) commented on infant formulae
supplemented with probiotics (and/or prebiotics) [2]. Based
on the evidence searched up to January 2010, it was* Correspondence: hania@ipgate.pl
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Warsaw 01-183, Poland
© 2013 Szajewska and Chmielewska; licensee
the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumconcluded that these formulae do not raise safety concerns
with regard to growth. The Committee evaluated only
studies in which infant formulae were supplemented with
probiotics and/or prebiotics during the manufacturing
process. Studies in which probiotics/prebiotics were
not introduced during the manufacturing process, but
administered thereafter, for example in capsules, the
contents of which were added to infant formulae,
were excluded. Given this, and considering the fact
that new studies have been published, the present review
was undertaken to update data on the efficacy of using
probiotic-supplemented formulae. The main objective was
to determine the effects of supplementation of infant
formulae with Bifidobacterium lactis Bb12 (B lactis)
and/or Lactobacillus rhamnosus GG (LGG) compared
with unsupplemented formula administered in early infancyBioMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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infants. The choice of the probiotic strains was determined
by the facts that both are widely available in many countries
and are commonly used in (or with) infant formulae.
Methods
For this systematic review, we followed the methods
described elsewhere [2]. In brief, the Cochrane Central
Register of Controlled Trials (CENTRAL, the Cochrane
Library), MEDLINE, and EMBASE databases were
systematically searched in June 2013 by both authors
independently, with no language restrictions. The following
search terms were used in different combinations:
Bifidobacterium or Bifidobacterium bifidum or B bifidum
or B. bifidum or B lactis or B. lactis or B lactis Bb12
or B. lactis Bb12 or Bifidobacterium animalis or B. animalis
or Bifidobacterium animalis ssp lactis or CNCMI-3446 or
Lactobacillus or Lactobacillus rhamnosus or Lactobacillus
rhamnosus GG or L. rhamnosus GG or LGG; formula or
formulae or milk; growth or anthropometry or weight or
length or head circumference or development or physical
development; newborn or infant or infant* or infants or
child or children or child*. For the full PubMed electronic
search strategy, see Additional file 1: Table S1. The reference
lists from identified studies and key review articles were also
searched. Letters to the editor and abstracts from scientific
meetings were excluded unless a full set of data was
obtained from the authors. Nestlé Nutrition Institute (NNI)
was contacted for unpublished data.
The search was restricted to randomized controlled
trials (RCTs) carried out in healthy term infants. Participants
in the experimental group received infant formulae supple-
mented with B lactis (depending on taxonomic classification
also known as B bifidum, B lactis Bb12, B animalis
ssp lactis CNCMI-3446), Lactobacillus rhamnosus GG
ATCC 53103 (LGG), or a combination of these 2
strains. Studies in which probiotics were either added
to a formula during the manufacturing process or
were administered separately, for example in capsules,
the contents of which were added to infant formula,
were considered for inclusion. Formulae manufactured
from cow’s milk proteins or any other proteins, as
well as formulae based on protein hydrolysates, were
eligible for inclusion. Subjects in the experimental group
received the study formula with probiotic(s), and subjects
in the control group received the same formula without
probiotic supplementation. If other comparisons were made
(for example, one trial [3] used formula mixed with another
probiotic strain [L reuteri ATCC 55730] as a control), these
other arms are not evaluated here. This is because the
objective of this review was to evaluate the effect, if any, of
supplementation of infant formula with probiotics such as
B. lactis or LGG or their combinations only, and not of other
formula differences. Also, we did not evaluate here breast-fedreference groups. The administration of infant formula
had to start in early infancy (below 4 months of age).
The primary outcome measures of interest were growth
parameters recommended by the Institute of Medicine
(IOM), i.e., weight, length, and head circumference. The
secondary outcome measures were body mass index
(BMI), body composition, skinfold, and dual-energy X-ray
absorptiometry (DXA) [1].
Titles and abstracts of all identified studies were
screened, and the full text of each potentially relevant
trial was retrieved. The reviewers independently applied
the inclusion criteria to each trial assessed as relevant.
Differences in opinion concerning the eligibility of the
studies for the review were resolved by discussion. Data
extraction was performed with use of standard data-
extraction forms. We contacted by email the authors of
the studies that reported growth but did not provide data.
However, we failed to obtain additional growth data. NNI
provided us with data from one clinical trial that was pub-
lished as an abstract only [4]. Moreover, in the study by
Urban et al. [5], unlikely data of head circumference incre-
ments of about 4.7 cm per month were found. These data
were compared with the original statistical report made
available to us by NNI. As it turns out, by mistake, instead
of showing data on head circumference, the authors
showed data on BMI. Here, the correct data are presented.
The risk of bias in the studies meeting the inclusion
criteria was assessed independently by the reviewers with
the implementation of The Cochrane Collaboration’s tool
for assessing risk of bias. The following criteria were used:
adequacy of sequence generation, allocation concealment,
and blinding of participants, personnel and outcome
assessors; and extent of loss to follow-up, i.e., the
proportion of patients in whom the investigators were
not able to determine outcomes (incomplete outcome data).
Low risk of bias was indicated by an answer of ‘yes’, and a
high risk, by an answer of ‘no’ [6].
The data were analyzed using RevMan ([Computer
program]. Version 5.2. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2012). The mean
difference (MD) between the treatment and control groups
was selected to represent the difference in continuous
outcomes (with 95% confidence interval, CI). Heterogeneity
was quantified by χ2 and I2, which can be interpreted as the
percentage of the total variation between studies that is
attributable to heterogeneity rather than to chance. A value
of 0% indicates no observed heterogeneity, and larger
values show increasing heterogeneity. If heterogeneity was
not revealed, we present results of only the fixed effects
model. If there was substantial heterogeneity (over 50%),
the analyses were based on the random effects model.
Although funnel plots to determine publication bias were
planned, there were too few studies to warrant generation
of a funnel plot.
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For a flow diagram documenting the identification
process for eligible trials, see Additional file 2: Figure S1.
Table 1 summarizes the key characteristics of included
trials. Among them, 7 RCTs assessed the effects on
growth of infant formulae supplemented with B lactis
during early infancy [3-5,7-10]. These formulae differed
mainly with regard to protein (although all had similar
energy densities through adjustment of the fat content),
and included infant formula with 2.2 g protein/100 kcal
[3]; reduced protein (1.8 g protein/100 kcal) infant formula
[4]; reduced protein (1.8 g protein/100 kcal) infant formula
supplemented with long-chain polyunsaturated fatty acids
[7]; acidified infant formula (2 g protein/100 kcal) [5,9]; par-
tially hydrolyzed 100% whey formula (2.2 g protein/100 kcal)
[8]; and reduced protein (1.9 g protein/100 kcal),
partially hydrolyzed 100% whey formula [10]. Two
RCTs evaluated the effects on growth of formulae
supplemented with LGG (standard infant formula
[11], extensively hydrolyzed casein formula, and partially
hydrolyzed whey-casein [60:40] formula [12]. Two RCTs
that evaluated the effects of the administration of a





Barclay 2003 (Italy) [4]
plus unpublished data
Healthy term newborns,
≤ 28 d of life at enrollment;
Bb12 (3 × 107
(1.8 g/100 kca
BW 2500 to 4200 g
Gibson 2009 (Australia) [7] ≥37 wk gestation,
BW 2500–4500 g, ≤10 d
Bb12 (3.85 × 1
in reduced pr
(n = 62/72)
Holscher 2012 (USA) [8] Healthy term infants (7 wk) Bb12 (10 6 CFU
(2.2 g protein/
Urban 2008 (South Africa)
[5] plus unpublished data
Healthy term infants born to





Healthy term infants born




Weizman 2006 (Israel) [3] Healthy term infants <4 mo Bb12 (1 × 107
(2.2 g protein/
Ziegler 2003 (Germany) [10] Healthy term infants (6–10 d) Bb12 (3.6 × 10
protein (1.9 g/
pHF (n = 28/4
LACTOBACILLUS GG
Scalabrin 2009 (USA) [12] Healthy term infants (14 d) LGG (108 CFU
formula (n = 6
Vendt 2006 (Estonia &
Finland) [11]
Healthy term infants (≤2 mo) LGG (107 CFU
Bb12, B lactis Bb12; BF, breastfeeding; BW, birth weight; CF, control formula; CFU, co
long chain polyunsaturated fatty acids; LGG, Lactobacillus rhamnosus GG; pHF, parti
* HIV (-) with full follow-up.
** name used in the publication B lactis CNCM I 3446.growth was not assessed [13,14]. An attempt was
made to contact the authors, but with no success.
Thus, these 2 RCTs were excluded. See Additional file 3:
Table S2 for a complete list of excluded trials with reasons
for exclusion.
The duration of the intervention and time of follow-up
ranged from 4 weeks to 7 months. The doses of the pro-
biotic used ranged from 106 to 3.6 × 109 colony-forming
units (CFU) per 1 gram of formula. The participants in
all of the included trials were healthy infants born at
term. Two studies included newborns born to HIV-positive
mothers and analyzed only those infants who were
HIV-negative [5,9].
Methodological quality (Table 2) varied among the
studies, but in general it was moderate. In four trials
[4,5,9,11], the dropout rate was very high. For example,
in the study by Urban et al. [5], out of 88 random-
ized infants, only 57 (64.7%) were available for ana-
lysis; in the study by Barclay et al. [4], out of 111
randomized infants, only 56 (50%) were available for
analysis.
Tables 3 and 4, and Figures 1, 2, 3 and 4 summarize
the main results of this review.Comparison Duration of
intervention
(follow-up)
CFU) in reduced protein
l) IF (n = 29/53)
Reduced protein
(1.8 g/100 kcal)
IF (n = 27/58)
4 mo (4 mo)
08 CFU/100 kcal + LCPUFA
otein IF (1.8 g protein/100 kcal)
Standard IF (n = 62/70) 7 mo (7 mo)
/g) in pHF 100% whey
100 kcal) (n = 41/50)
pHF 100% whey
(n = 34/43)
6 wk (6 wk)
o data) in acidified IF
00 kcal) (n = 29/45*)
Acidified IF (n = 28/43*) 119 d (182 d)




6 mo (182 d)
CFU/g) in IF
100 kcal) (n = 20)
Standard IF (n = 19) 4 wk (4 wk)
9 CFU /g) in reduced
100 kcal) 100% whey
0)
Reduced protein, 100%
whey pHF (n = 27/40)
4 mo (112 d)






/g) in IF (n = 51/60) IF (n = 54/60) 6 mo (6 mo)
lony forming units; EH, extensively hydrolyzed; IF, infant formula; LCPUFA,
ally hydrolyzed.
Table 3 Formulae supplemented with B lactis
Outcome RCTs Participants Effect estimate
MD (95% CI), fixed effect model
Weight gain (g/day) 4 266 0.96 (−0.70 to 2.63) (random)
• Reduced protein (1.8 g/100 kcal) IF 1 56 1.40 (−1.73 to 4.52) (random)
• Reduced protein (1.8 g/100 kcal) IF with LCPUFA 1 98 1.71 (−0.7 to 4.12) (random)
• Reduced protein (1.9 g/100 kcal) pHF 1 55 −1.83 (−5.35 to 1.69) (random)
• Acidified formula (2 g protein/100 kcal) 1 57 3.24 (−0.18 to 6.66) (random)
Length (mm/month) 4 261 −0.39 (−1.32 to 0.53)
• Reduced protein (1.8 g/100 kcal) IF 1 56 1.28 (−1.28 to 3.83)
• Reduced protein (1.8 g/100 kcal) IF with LCPUFA 1 93 −0.60 (−2.39 to 1.18)
• Reduced protein (1.9 g/100 kcal) pHF 1 55 −0.83 (−2.27 to 0.60)
• Acidified IF (2 g protein/100 kcal) 1 57 −0.27 (−2.42 to 1.89)
Head circumference (mm/month) 3 207 0.56 (−0.17 to 1.30)
• Reduced protein (1.8 g/100 kcal) IF 1 56 0.36 (−0.79 to 1.51)
• Reduced protein (1.8 g/100 kcal) IF with LCPUFA 1 95 0.27 (−0.91 to 1.45)
• Acidified IF (2 g protein/100 kcal) 1 56 1.51 (−0.09 to 3.11)
Body mass index (BMI)(kg/m2/month) 3 206 0.09 (−0.05 to 0.22)
• Reduced protein (1.8 g/100 kcal) IF 1 56 −0.01 (−0.25 to 0.24)
• Reduced protein (1.8 g/100 kcal) IF with LCPUFA 1 93 0.10 (−0.10 to 0.30)
• Acidified IF (2 g protein/100 kcal) 1 57 0.17 (−0.10 to 0.43)
Final weight percentiles (IF 2.2 g protein/100 kcal) 1 39 −2.7 (−13.37 to 7.97)
Final length percentiles (IF 2.2 g protein/100 kcal) 1 39 −2.00 (−12.75 to 8.75)
Final HC percentiles (IF 2.2 g protein/100 kcal) 1 39 −7.5 (−18.15 to 3.15)
HC, head circumference; IF, infant formula; LCPUFA, long-chain polyunsaturated fatty acids; MD, mean difference; pHF, partially hydrolyzed formula; RCTs,
randomized controlled trials.
Summary of the results.
Table 2 Methodological quality of included trials
Reference Adequate sequence generation? Allocation concealment? Blinding? Incomplete outcome
data addressed?
B LACTIS
Barclay 2003 [4] plus unpublished data Unclear* Yes Yes No**
Gibson 2009 [7] Yes Yes Yes Yes
Holscher 2012 [8] Unclear Unclear Yes Yes
Urban 2008 [5] plus unpublished data Yes Yes Yes No**
Velaphi 2008 [9] Unclear Unclear Yes No**
Weizman 2006 [3] Yes Unclear Yes Yes
Ziegler 2003 [10] Unclear Unclear Unclear No**
LACTOBACILLUS GG
Scalabrin 2009 [12] Yes Yes Yes No
Vendt 2006 [11] Yes Unclear Yes Yes
In all cases, an answer of ‘yes’ indicates a low risk of bias, and an answer of ‘no’ indicates a high risk of bias.
* The randomization procedure was changed during the study because of a problem with formula supply.
** A drop-out rate >20%.
Szajewska and Chmielewska BMC Pediatrics 2013, 13:185 Page 4 of 10
http://www.biomedcentral.com/1471-2431/13/185
Table 4 Formulae supplemented with Lactobacillus GG
Outcome RCTs Participants Effect estimate
MD (95% CI), fixed
effect model
Weight (g)
• At entry 1 105 −440 (−487 to −393)
• After 3 mo 1 105 −323 (−374 to −271)
• At 6 mo 1 105 −150 (−204 to −96)
Length (mm)
• At entry 1 105 −18 (−20 to −16)
• After 3 mo 1 105 −12 (−13 to −11)
• At 6 mo 1 105 −7 (−8 to −6)
Head circumference (mm)
• At entry 1 105 −5 (−6 to −4)
• After 3 mo 1 105 −3 (−4 to −2)
• At 6 mo 1 105 0.0 (−0.8 to 0.8)
Change in standard
deviation score
• Weight after 3 mo 1 105 0.33 (0.24 to 0.42)
• Weight at 6 mo 1 105 0.44 (0.39 to 0.49)
• Length after 3 mo 1 105 0.27 (0.16 to 0.38)
• Length at 6 mo 1 105 0.37 (0.27 to 0.47)
• HC after 3 mo 1 105 0.19 (0.14 to 0.24)
• HC at 6 mo 1 105 0.27 (0.23 to 0.31)
HC, head circumference; MD, mean difference; RCTs, randomized controlled trials.
Summary of the results.
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The effect of supplementation of infant formulae with
B lactis on growth parameters was studied in 7 RCTs
[3-5,7-10]; thus, in comparison with the 2010 analyses,
4 new RCTs were added to this analysis or were updated.
Weight gain
The effect of B lactis supplementation on weight gain was
studied in 4 RCTs [4,5,7,10]. No significant differences
between the experimental groups and the control groups
were reported in any of the studies. The pooled results of
4 RCTs (n = 266) revealed no significant difference in
weight gain between the probiotic and control groups
(MD 0.90 g/day; 95% CI −0.51 to 2.32, fixed effect model).
Heterogeneity was found (I2 54.1%); however, there was
still no significant difference in weight gain between the
probiotic and control groups in the random effect model
(MD 0.96 g/d; 95% CI −0.70 to 2.63; I2 31.7%) (Figure 1).
Length gain
The effect of B lactis supplementation on length gain
was studied in 4 RCTs [4,5,7,11]. None of the individual
trials reported significant differences between the
study groups. The pooled results of 4 RCTs (n = 261)also revealed that infants fed formula supplemented
with B lactis had similar length gain compared with infants
fed unsupplemented formula (MD −0.39 mm/month; 95%
CI −1.32 to 0.53). No significant heterogeneity was found
(I2 = 0%) (Figure 2).Head circumference gain
The effect of B lactis supplementation on head circum-
ference gain was studied in 3 RCTs [4,5,7]. No signifi-
cant differences between the experimental groups and
the control groups were reported in any of the studies.
The pooled results of the 3 trials (n = 207) revealed no
significant difference between the probiotic and control
groups in head circumference gain (MD 0.56 mm/month;
95% CI −0.17 to 1.30; I2 = 0%) (Figure 3).BMI
The effect of B lactis supplementation on BMI was studied
in 3 RCTs [4,5,7]. No significant differences between the
experimental groups and the control groups were reported
in any of the studies. The pooled results of 3 trials
(n = 206) revealed no significant difference between the pro-
biotic and control groups in BMI (MD 0.09 kg/m2/month;
95% CI −0.05 to 0.22; I2= 0%) (Figure 4).Body composition, skinfold, DXA
None of the studies reported on any of these predefined
outcomes.Other presentations of growth outcomes
Urban et al. [5] reported no differences between the study
groups in Z-scores for weight-for-age, length-for-age, and
head circumference-for-age (data not shown but available
upon request). Velaphi et al. [9] demonstrated that there
was an increase in z scores for all studied formulae;
however, no significant differences were found for
weight-for-age (P = 0.22), length-for-age (P = 0.56), head
circumference-for-age (P = 0.66), and weight-for-length
(P = 0.13) between the study groups. In the original
publication, data were presented as figures only, so
data are not reported here. Weizman et al. [3] reported
that the use of standard infant formula supplemented
with B lactis, compared with unsupplemented standard
infant formula, had no effect on growth assessed by
final weight, length, and head circumference percentiles
(see Additional file 4: Figure S2). Holscher et al. [8]
reported that mean weight percentiles generated from
the World Health Organization growth charts did not
differ between infants fed formula with 2.2 g protein
(100% partially hydrolyzed whey)/100 kcal or the
same formula supplemented with B lactis (data not
presented in the original study).
Figure 1 B lactis vs. control. Administration started in infants <4 mo of age. Outcome: weight gain (g/day).
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One RCT [11] involving 105 infants fed standard
infant formula supplemented with LGG provided data
on growth. At entry, despite randomization, the
groups were not equivalent. Compared with the con-
trol group, children randomly assigned to the LGG
group were significantly smaller with regard to
weight, length, and head circumference. These differ-
ences between groups remained significant at 3 and
6 months of age, except for head circumference at
6 months (see Additional file 5: Figure S3). However,
compared with children receiving unsupplemented
formulae, those receiving formula supplemented with
LGG grew better, as documented by significantly higher
changes in standard deviation scores (see Additional file 6:
Figure S4). One further RCT investigated the impact
on growth in infants fed extensively hydrolyzed casein
formula with or without LGG supplementation [12].
In principle, no significant differences between the
study groups were found with regard to growth rates
from day 14 to day 30, 120, or 150. Data are not
presented, but available in the original publication
and upon request.Discussion
Summary of findings
The objective of this review was to update evidence
on the effects of supplementation compared with
non-supplementation of infant formulae with B lactis
and/or LGG on the growth of healthy infants. It was
not designed to evaluate the effects of supplementation
compared to breast milk. As it is desirable that growth
measurements should be taken during the period when
infant formula remains an exclusive source of nutrition
for an infant, we focused on supplementation during
early infancy. In general, B lactis supplementation results
in growth similar to what is found in unsupplemented
infants. Caution is needed not to over-interpret these
results as in some of the studies only a subset of infants was
available for analysis. With regard to LGG supplementation,
data limited to only one trial suggest that infants
who received infant formula supplemented with LGG
grew better. The interpretation of these findings is
difficult. First, the groups were not equivalent at
entry into the study. Second, the mechanisms as to
how LGG supplementation might influence weight and
length gain are not clear. Finally, no such effect was
Figure 2 B lactis vs. control. Administration started in infants <4 mo of age. Outcome: length (mm/month).
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with LGG.
None of the studies evaluated the effect of probiotic sup-
plementation on body composition. The major advantage
of this assessment is that it allows more precise assessment
of the metabolic effects of ingredients. It is also considered
as a potential long-term predictor of health outcomes. Body
composition is, however, difficult and expensive to measure;
the best method of measurement requires DXA [1].
Strengths and limitations
This systematic review largely focuses on a single, well-
defined probiotic (B lactis). Furthermore, it is based on
the largest number of studies, and it includes unpub-
lished data. However, there are limitations to this review.
The number of trials with a particular type of probiotic
and/or a specific type of formula was small. The meth-
odological quality and the quality of reporting the study
findings were variable and sometimes poor, especially in
earlier published studies. Other potential limitations in-
clude unclear sequence generation, unclear allocation
concealment, and a very high dropout rate in some ofthe included trials. The findings are, therefore, likely to
be affected by a varying degree of bias.
The sample sizes in some trials were small. The issue
of statistical power in studies evaluating infant formulae
has been addressed by a number of scientific organizations.
According to ESPGHAN, as a minimum, the study should
have a power to detect a difference in weight gain equal to
0.5 SD [15]. The IOM stated that the sample sizes
must be large enough to ensure sufficient statistical
power in follow-up studies, particularly if these studies are
carried out years after the child has ceased infant formula
consumption. The IOM recommends a sample size of
52 children per group to detect a moderate-effect size
difference and a sample size of 140 children per group to
detect an intermediate-effect size difference (i.e., between
small and moderate) (with 80% power). The IOM also
stated that ‘unless there are compelling reasons to do
otherwise, the committee recommends having sufficient
power to detect differences between groups of 0.20 SD
or less when estimating sample-size needs in follow-up
studies.’ The IOM suggests that ‘even effect sizes of this
magnitude can have important clinical implications’ [1].
Figure 3 B lactis vs. control. Administration started in infants <4 mo of age. Outcome: head circumference (mm/month)
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too small with insufficient power to identify relevant
effects on growth, and the follow-up periods in the trials
were short, the findings needs to be interpreted with
caution.Figure 4 B lactis vs. control. Administration started in infants <4 mo of aFinally, to assess growth, the duration of the study should
be at least 3 months, and the IOM has recommended a 120-
day growth study to assess the ability of an infant formula to
sustain normal growth [1]. In the included trials, the duration
of the intervention in some of the studies was much shorter.ge. Outcome: BMI (kg/m2/month).
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The findings of this systematic review are in line with the
previous report by ESPGHAN [2]. Also, a more recent
systematic review (search date: 2010) found that probiotic
supplementation did not have any significant effect on
growth (weight gain, length gain, or head circumference)
in boys or girls [16]. None of the included studies reported
weight loss. As with this review, the authors noted that
the studies had small sample sizes and short follow-up
periods. In contrast to this review, all probiotics were
evaluated together as a class of agents, with no analyses
based on only one type of probiotic microorganism.
Beyond early infancy (starting >4 months of age), evidence
from 4 RCTs [17-20], previously reviewed by ESPGHAN,
suggests that B lactis supplementation (in combination with
Str thermophilus with or without L helveticus) of formula is
also associated with adequate growth. No new studies that
analyzed the effect of B lactis supplementation of formula
beyond early infancy have been published since then. How-
ever, as previously recommended by ESPGHAN, caution is
needed when interpreting these results for several reasons.
First, due to the methodological limitations of the study and
a high risk of bias. Second, caution is needed when interpret-
ing these results due to the wide age range (from 6 to
36 months). Considering the differences in growth velocity
and regulation of growth in young infants and toddlers, no
firm conclusions can be made [2]. No data on the effects of
LGG supplementation were identified.
Finally, recent evidence has suggested that compared
with higher protein content in infant formulae, lower
protein content is associated with a lower weight in
infants up to 2 years of age [21]. The protein content in
the included RCTs differed, and it ranged from 1.8 g of
protein/100 kcal to 2.2 g of protein/100 kcal. One may
speculate that these differences may have had an impact
on growth. However, as the data are limited, and no dir-
ect comparisons of a high- vs. low-protein formula were
made, no firm conclusions can be made based on this
review. Considering the potential anti-obesity effect of a
low-protein infant formula, such studies are warranted.
Conclusions
The effect on growth is an important part of the safety evalu-
ation of any product used in infants [22]. Supplementation of
infant formulae with B lactis results in growth similar to
what is found in infants fed unsupplemented formulae.
Limited data do not allow one to reach a conclusion regard-
ing the effect of LGG supplementation on infant growth.
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